SEARCH · PubMed Health

Results for “Probiotic”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 523 records · Page 29Linked to original sources

PubMed2005

Evaluation of five probiotic products for label claims by DNA extraction and polymerase chain reaction analysis.

Label claims were evaluated for five probiotic products. Specific oligonucleotide primers were designed for 11 species from the Bifidobacterium, Lactobacillus, and Streptococcus genera. Polymerase chain reaction, gel electrophoresis, and amplicon excision with DNA sequencing were performed: Sequence analysis and DNA homology comparisons followed. Bifidobacterium bifidum was not detected in two of the five samples by PCR analysis. Also, Lactobacillus species were found in two of the five product samples for which the species was not listed as an ingredient. We conclude that (1) lack of B. bifidum in two probiotic products may be attributed to different preparation standards among probiotic manufacturers, and (2) identificaition of additional Lactobacillus species may represent contamination of the samples related to the fact that manufacturers utilize shared equipment to produce all probiotics and PCR is a highly sensitive technique.

Bifidobacterium↗

PubMed2005

Do probiotics reduce adult lactose intolerance? A systematic review.

PURPOSE: To assess the efficacy of oral probiotics in adults with lactose intolerance through a systematic review of its effects on symptoms and breath hydrogen tests, and whether adding probiotics to nonfermented dairy products decreases lactose intolerance at that meal. METHODS: We searched randomized controlled trials published between 1966 and December 2002. Databases in the search strategy included Medline and AMED. We reviewed references of clinical trials and contacted authors of major articles and manufacturers of probiotic commercial products. Quality assessment was based on the McMaster guides and was performed by 5 independent reviewers. Data extraction was performed by 2 reviewers. RESULTS: A master list of 90 articles was compiled. Ten articles met inclusion and exclusion criteria and were consistent with our clinical question. Of the 9 studies that measured breath hydrogen, 3 were positive, 3 were negative, and 3 had both positive and negative results. Of the 7 studies that measured symptoms, 1 yielded positive results, 5 were negative, and 1 had both positive and negative outcomes. CONCLUSIONS: Probiotic supplementation in general did not alleviate the symptoms and signs of lactose intolerance in adults in this review. Some evidence suggests that specific strains, concentrations, and preparations are effective. Further clinical trials of specific strains and concentrations are necessary to delineate this potential therapeutic relationship.

Administration, Oral↗

PubMed2005

One-year application of probiotic strain Enterococcus faecium M-74 decreases serum cholesterol levels.

OBJECTIVES: To investigate the impact of long-term orally administered probiotic strain Enterococcus faecium (EF) M-74 enriched with selenium on lipid profile (total cholesterol, LDH, HDL, and triglycerides) in humans. BACKGROUND: The discovery that hypercholesterolemia plays a major role in the development of atherosclerosis has led to a number of pharmacological and non-pharmacological (including dietary) approaches resulting in its elimination. Up to now, the question of supposed hypocholesterolemic effect of probiotics has not been definitely established. METHODS: 43 volunteers were randomized into two groups. Participants were given single capsule a day containing 2x10(9) of EF M-74 plus 50 microg of organically bound selenium (E-group) or placebo (P-group). The study was double-blind and lasted 60 weeks. Peripheral blood was analyzed for lipid parameters before intervention, after 6, 12, 23, 44, and 56 weeks of capsule administration, and four weeks following interruption of administration. RESULTS: After 56 weeks of application, decrease in total cholesterol in E-group (17/3 women/men, mean age 75.4+/-1.5 year) was observed (5.94+/-0.29 mmol/l at week 0 vs 5.22+/-0.25 mmol/l after 56 weeks, p<0.001). This reduction was achieved mainly due to a fall in LDL cholesterol (3.85+/-0.27 vs 3.09+/-0.21 mmol/l, p<0.001), as no significant alterations in HDL and triglycerides were noted. In placebo group (14/4, 78.1+/-1.7 year), no statistically important changes were observed after one-year capsule administration. CONCLUSIONS: In our study, the administration of E. faecium M-74 probiotic strain was associated with reduction of serum cholesterol concentration by 12% after 56 weeks. The crescent amount of facts on this issue gives a solid reason to assume that probiotics will find their place as a therapeutic alternative in human medicine. (Tab. 4, Fig. 4, Ref: 36.)

Aged↗

PubMed2005

Evaluation of labeling and content of probiotics available in the Czech Republic.

Probiotics are live cultures of mikroorganisms which are good for human health and are used in human medicine as a treatment. Advantageous effect on a human health was proved in many studies in Europe and in the USA. On the other hand, many studies described lack of information about products containing probiotics - in particular the real bacterial strain or quantity of bacteria. We tried to evaluate thirteen products containing probiotics available in the Czech Republic. In all cases the leaflets contained information about the species and amount of bacteria (from seven products containing more than one species of bacteria were only in two cases declared the quantity of particular bacteria, in five cases was declared just the total quantity of bacteria). The declared species of bacteria were cultured in all tested products. Concluding; the information on the leaflets of probiotic products is sufficient for a clinical practice and the real species and quantity of bacteria come up to declared data.

Bacteria↗

PubMed2006

[The effects of probiotics on symptoms of irritable bowel syndrome].

BACKGROUND/AIMS: Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) tract disorder that has heterogeneous clinical presentations such as abdominal pain, diarrhea, constipation, and abdominal distension. It is known that several mechanisms are involved in the pathogenesis of IBS. Probiotics may target one or more pathophysiologic pathways in IBS and may improve the symptoms of IBS. However, the results of studies about probiotics on IBS are controversial. Therefore, the aim of this study was to evaluate the effect of probiotics on GI symptoms and intestinal gas volume changes in patients with IBS. METHODS: Forty patients were randomly allocated to be treated with Medilac DS (Bacillus subtilis, Streptococcus faecium) (n=20) or placebo (n=20) in a double-blind, prospective manner. The change in intestinal gas volume and symptom scores after 4-week treatment were evaluated for the efficacy. RESULTS: There was no significant difference in bloating, frequency of gas expulsion, frequency of defecation, and hardness of stool before and after the treatment. However, the severity of abdominal pain and the frequency of abdominal pain decreased significantly in Medilac DS group (2.4+/-1.3 cm/day --> 1.6+/-1.6 cm/day, 1.7+/-1.3/day --> 1.0+/-1.0/day) (p=0.044, p=0.038), but not in placebo group (2.1+/-2.0 cm/day --> 1.8+/-2.1 cm/day, 1.3+/-1.2/day --> 1.4+/-1.9/day). In both groups, intestinal gas volume at baseline, after 2-week treatment, and after 4-week treatment did not show significant change. Medilac DS was well tolerated without adverse events. CONCLUSIONS: Medilac DS is a safe and useful probiotic agent for the treatment of abdominal pain in patients with IBS.

Abdominal Pain↗

PubMed2006

Lactic acid bacteria as probiotics.

A number of Lactobacillus species, Bifidobacterium sp, Saccharomyces boulardii, and some other microbes have been proposed as and are used as probiotic strains, i.e. live microorganisms as food supplement in order to benefit health. The health claims range from rather vague as regulation of bowel activity and increasing of well-being to more specific, such as exerting antagonistic effect on the gastroenteric pathogens Clostridium difficile, Campylobacter jejuni, Helicobacter pylori and rotavirus, neutralising food mutagens produced in colon, shifting the immune response towards a Th2 response, and thereby alleviating allergic reactions, and lowering serum cholesterol (Tannock, 2002). Unfortunately, most publications are case reports, uncontrolled studies in humans, or reports of animal or in vitro studies. Whether or not the probiotic strains employed shall be of human origin is a matter of debate but this is not a matter of concern, as long as the strains can be shown to survive the transport in the human gastrointestinal (GI) tract and to colonise the human large intestine. This includes survival in the stressful environment of the stomach - acidic pH and bile - with induction of new genes encoding a number of stress proteins. Since the availability of antioxidants decreases rostrally in the GI tract production of antioxidants by colonic bacteria provides a beneficial effect in scavenging free radicals. LAB strains commonly produce antimicrobial substance(s) with activity against the homologous strain, but LAB strains also often produce microbicidal substances with effect against gastric and intestinal pathogens and other microbes, or compete for cell surface and mucin binding sites. This could be the mechanism behind reports that some probiotic strains inhibit or decrease translocation of bacteria from the gut to the liver. A protective effect against cancer development can be ascribed to binding of mutagens by intestinal bacteria, reduction of the enzymes beta-glucuronidase and beta-glucosidase, and deconjugation of bile acids, or merely by enhancing the immune system of the host. The latter has attracted considerable interest, and LAB have been tested in several clinical trials in allergic diseases. Characteristics ascribed to a probiotic strain are in general strain specific, and individual strains have to be tested for each property. Survival of strains during production, packing and storage of a viable cell mass has to be tested and declared.

Antibiosis↗

PubMed2006

Influencing health through intestinal microbiota modulation and probiotics.

Science has progressed fast in providing answers to probiotic health benefits to the consumers. This symposium also proves that progress is fast. However, several challenges still need to be solved and more effective strains and strain combinations discovered. This will pave the way from good probiotics to specific products for clearly identified target populations. The intestinal microbiota and its interaction(s) with probiotics challenges researchers to turn to the next new page to discover new approaches and treatment modalities that utilize probiotics as means of providing good nutrition with clear health benefits to all consumers.

Clinical Trials as Topic↗

PubMedDate not supplied

Supplementation with oral probiotic bacteria maintains cutaneous immune homeostasis after UV exposure.

Probiotic bacteria have been shown to modulate the immune system of the gut and protect against infectious and inflammatory diseases of the gastro-intestinal tract. Ultraviolet radiation (UVR) is known to alter the cutaneous and systemic immune systems implicated in the development of skin tumors. In this study we investigated whether oral probiotics are able to modulate the immune system of the skin using hairless Skh:hr1 mice exposed to an acute dose of UVR. We show that nutritional supplementation with Lactobacillus johnsonii (La1) at 10(8) cfu/day for 10 days was able to protect against the UVR-induced suppression of contact hypersensitivity, the decreased epidermal Langerhans cell density and the increased IL-10 serum levels. In the absence of UV exposure, probiotic bacteria had no detectable effect on the immune system of the skin, thus acting only to re-establish skin homeostasis. In conclusion, our data demonstrate that ingested probiotic bacteria can maintain cutaneous immune capacity after UV exposure.

Animals↗

PubMed1998

[Probiotics in childhood].

The Probiotics (Lactic acid bacteria) represent a nutritional live microbial supplement that positively affects host by enhancing the microbial balance. A survey is made of the most relevant studies concerning the use of probiotics in the prevention and treatment of infantile acute diarrhoea (by rotavirus or other agents), pseudomembranous colitis, hospital-acquired and antibiotic-associated diarrhoeas. Although the probiotics mechanism of action is not yet completely understood, it has been hypothesized that they exert an inhibitory effect on the intestinal inflammation by immune response modulation. Due to this property, the use of probiotics has therefore been suggested in other severe diseases such as chronic inflammatory bowel diseases, rheumatoid arthritis, food allergy, atopic dermatitis and as immunoadjuvant for oral vaccines.

Child↗

PubMed1998

European market developments in prebiotic- and probiotic-containing foodstuffs.

A growing number of food manufacturers in western Europe are beginning to explore the commercial opportunities for foodstuffs containing health-promoting microbial food supplements (probiotics) and health-promoting non-digestible food ingredients (prebiotics). A prebiotic is considered to affect the host beneficially by selectively stimulating the growth and/or activity of one or a limited number of naturally present or introduced bacterial species in the colon, also leading to a claimed improvement in host health. Increasingly, probiotics and prebiotics are used in combination, this being termed a synbiotic (Gibson & Roberfroid, 1995). Throughout European history, fermented milk products in particular have been considered beneficial to health, but only in recent years has there been scientific support for these beliefs. Issues considered important to the continuing development of this growing market are proof of safety, proof of efficacy, consumer education, market positioning, price and appropriate health claims strategies. Until recently, much of the innovation in the use of probiotics and prebiotics has been in the dairy cabinet, with an ever-growing number and range of 'health-promoting' yoghurts and yoghurt-type fermented milk being made available to the European consumer, a market which is currently estimated to be worth in excess of $US2 billion per annum (Hilliam et al. 1997). However, prebiotics are beginning to find increasing application outside the dairy sector, particularly in baked goods. A key driver behind the broadening application of prebiotics has been the pro-active stance taken by key prebiotic suppliers such as Beghin-Say, Orafti and Cosucra. To date, market activity in probiotic- and prebiotic-containing foods has centred around three health propositions, namely improving general gut health, lowering blood cholesterol and improving the body's natural defences.

Colon↗

PubMed1996

PCR methods for identification and specific detection of probiotic lactic acid bacteria.

Probiotics are defined as "microbes improving animal feed." Three lactic acid bacteria, previously selected as probiotic for pig feeding, were identified by sequencing the variable V1 region of the 16S rDNA after PCR amplification primed in the flanking constant region. A VR region showing strong nucleotide differences between the three probiotic and the reference strains was delimited. Oligonucleotides specific for each strain were designed. A specific assay for probiotic detection was developed, based on a PCR reaction with three primers.

Animal Feed↗

PubMed2026

Screening, isolation, and identification of Latilactobacillus sakei strains from kimchi with potential probiotic properties.

UNLABELLED: The study aimed to screen 40 lactic acid bacterial isolates from kimchi types to isolate Latilactobacillus (L.) sakei strains for their probiotic potential. Based on random amplified polymorphic DNA-based initial screening, 16 S rRNA-based phylogeny, and species-specific PCR, three sakei strains (RKA, RKC, and TAB) were selected for evaluating their probiotic and functional attributes. The selected strains demonstrated probiotic characteristics, including acid tolerance (33-85%), bile salt tolerance (49-68%), cell surface hydrophobicity with ethyl acetate (11.5-25.6%) and hexane (21.0-47.4%), and auto-aggregation (12.6-44.0%). The safety of strains was assessed by γ-hemolytic activity and susceptibility to most tested antibiotics, including carbenicillin, clindamycin, chloramphenicol, ampicillin, erythromycin, and tetracycline, with resistance to cefoxitin and metronidazole. Both crude and cell-free supernatants (CFSs) of selected strains were tested for antimicrobial and antioxidant activities, as well as for cytotoxic effects against human colon adenocarcinoma (Caco-2) cells. CFSs displayed DPPH and ABTS radical scavenging activities of 34.1-37.9% and 41.6-43.1%, whereas the crude ranged from 3.9 to 8.7% and 11.0-17.3%, respectively, supported by the presence of the sod and katA genes. All strains showed good resistance to hydrogen peroxide at various concentrations. Notably, RKC showed superior antimicrobial activity against Escherichia coli, Bacillus subtilis, Pseudomonas aeruginosa, Staphylococcus aureus, and Candida albicans, compared to RKA and TAB. No significant cytotoxicity was observed in Caco-2 cells. In summary, these findings indicate the probiotic potential of L. sakei isolates and the preliminary functional properties of their CFSs; further genome-based characterization of selected strains is warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at https://doi.org/10.1007/s13205-026-04978-7.

Antimicrobial↗

PubMed2000

The effect of probiotics on Clostridium difficile diarrhea.

Clostridium difficile is the leading cause of nosocomially acquired intestinal infection in the United States, affecting virtually all cases of pseudomembranous colitis and up to 20% of cases of antibiotic-associated diarrhea. Even after receiving antibiotic treatment with either metronidazole or vancomycin, 20% of patients will have recurrent Clostridium difficile diarrhea. An innovative approach to the problem involves the introduction of competing, nonpathogenic (probiotic) organisms into the intestinal tract to restore microbial balance. The theoretical premise behind this approach is that the protective intestinal microflora is damaged by antibiotic treatment; the initial antibiotic exposure thus leaves the host susceptible to colonization and subsequent infection by Clostridium difficile. A so-called "second-hit" to the intestinal microflora occurs when the infected host is treated with flagyl or vancomycin, further destroying susceptible bacterial flora. Probiotic agents, such as Lactobacillus GG and Saccharomyces boulardii, have been studied for the treatment of Clostridium difficile. We are currently running a prospective, randomized, placebo-controlled trial of Lactobacillus GG in combination with standard antibiotics for the treatment of Clostridium difficile infection. Although it is too early to draw statistically significant conclusions, two patterns seem to be emerging: Lactobacillus GG is effective in reducing the 3-wk recurrence rate of Clostridium difficile, and patients feel better when taking Lactobacillus GG, as compared with the placebo, with early disappearance of abdominal cramps and diarrhea. In conclusion, the use of probiotics for the treatment of primary and recurrent Clostridium difficile diarrhea looks promising. Patients seem to have less recurrent Clostridium difficile diarrhea and early symptomatic improvement when using the probiotic Lactobacillus GG.

Aged↗

PubMed1998

Characterisation and selection of probiotic lactobacilli for a preliminary minipig feeding trial and their effect on serum cholesterol levels, faeces pH and faeces moisture content.

Three out of 297 Lactobacillus strains isolated from pig faeces were selected for a feeding trial on account of their high bile-salt hydrolase (BSH) activity, bile-salt resistance, low pH tolerance and the production of antimicrobial substances. Two strains were identified as Lactobacillus johnsonii and one as Lactobacillus reuteri by DNA-DNA hybridisation. L. johnsoniii BFE 1061 produced a bacteriocin active against a range of lactic acid bacteria (LAB) and nonrelated bacteria including Clostridium perfringens. Six minipigs were maintained on a high-fat, high-cholesterol ('Western Style') diet for 17 weeks after which the diet was supplemented with the 'probiotic mixture' containing the above mentioned three Lactobacillus strains at 2 x 10(12) CFU per pig per day for five weeks. The mixture was given as a resuspended lyophilisate. During a two week follow-up period the minipigs received only the 'Western-style' diet without probiotic supplementation. A lowering effect on serum cholesterol levels was indicated after three weeks probiotic feeding, concomitant with an increase in the moisture content of the faeces and Lactobacillus cell numbers. Triglycerides, pH and number of lactic acid bacteria in faeces were not significantly influenced by probiotic supplementation.

Animals↗

PubMed2001

Selection of a potential probiotic Lactobacillus strain and subsequent in vivo studies.

The probiotic potential of a Lactobacillus strain, isolated from pig faeces, was assessed as a probiotic in piglets. The strain was examined for resistance to pH 2.0, 0.5% oxgall and antibiotics, and antimicrobial activities against enteric pathogenic bacteria. The probiotic strain, L. reuteri BSA131, was administered through the feed to 25 1-month-old Landrace piglets. The piglets were divided into five groups of five piglets each and fed with different diets for 28 days. The daily consumption of L. reuteri BSA131 was assigned into two groups by the concentration of 10(6) or 10(8) freeze-dried bacteria. Fecal samples were collected before, during, and after consumption. Lactobacilli and enterobacteria cell counts were determined in the fecal samples. The liveweight gains and feed consumption of the piglets were recorded daily. This study showed that strain BSA131 enhanced liveweight gains and feed conversion rates in piglets. It also showed a significant increase in lactobacilli cell counts and decreases in enterobacterial numbers in the fecal samples. Strain BSA131 was considered to be a potential probiotic for piglets, especially after weaning.

Animal Feed↗

PubMed1995

Effect of probiotic supplementation on serum/yolk cholesterol and on egg shell thickness in layers.

1. The effect of probiotic supplementation on egg production, on serum and yolk cholesterol and on egg shell thickness in 24 White Leghorn layers was studied from 28-38 weeks of age. 2. In 3 treatments the diet was supplemented with 0, 100 and 150 mg probiotic/kg food. 3. In the 100 mg probiotic group, egg production improved by 5%, and shell thickness improved slightly, with fewer thin-shelled eggs than in the control (8.6% compared to 18.6%). 4. The initial serum cholesterol concentration of 170.2 mg/dl in control birds remained similar throughout the 10-week experimental period, whereas in the 150 mg group the initial value of 176.5 mg/dl decreased to 114.3 mg by week 10. 5. Yolk cholesterol concentration was 14.69 mg in the control group and 11.28 and 11.37 mg/g in the 100 and 150 mg probiotic groups respectively. Overall mean total egg cholesterol was thus reduced by probiotic supplementation.

Animal Feed↗

PubMed1993

Probiotics and manipulation of rumen development and function.

There is good evidence that the bacterial and fungal probiotics are effective in the manipulation of rumen development and function. The effects of adherent Streptococcus bovis preparations were manifested by significant increase of adherent S. bovis bacteria and alpha amylase activity in the rumen wall of young ruminants. Fungal probiotics based on Saccharomyces cerevisiae and Aspergillus oryzae are rapidly gaining acceptance as a means of improving productivity in adult ruminants. However, fungal probiotics may also have a complementary role to bacterial probiotics in young animals. Dietary yeast improved performance of calves and lambs in terms of feed intake and live weight gain and Aspergillus foetidus was effective in altering rumen fermentation in newly weaned lambs.

Animals↗

PubMed2001

The role of probiotics in the treatment of intestinal infections and inflammation.

Clinical studies have established that certain probiotics are useful in a variety of intestinal disorders, including viral diarrhea, antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and traveler's diarrhea. Evolving data suggest that probiotics might be useful in the control of inflammatory diseases, treatment and prevention of allergic diseases, cancer prevention, and stimulation of the immune system, which may result in the reduction in respiratory disease. A review of current data regarding the most common probiotics is presented. It is important that probiotic use be directed by well-designed, placebo-controlled clinical studies published in peer-reviewed journals.

Journal Article↗